Fatigue performance and cyto-toxicity of low rigidity titanium alloy, Ti-29Nb-13Ta-4.6Zr
Fatigue performance and cyto-toxicity of low rigidity titanium alloy, Ti-29Nb-13Ta-4.6Zr
复制标题
DOI：
10.1016/s0142-9612(03)00069-3
复制
发表时间：
2003-07-01
期刊：
影响因子：
14
通讯作者：
Niinomi, M
中科院分区：
文献类型：
--
作者：
Niinomi, M
新型钛合金Ti-29Nb-13Ta-4.6Zr是一种新型的生物医用钛合金。这种新合金含有Nb、Ta和Zr等无毒元素。在本研究中，通过硬度测试和显微组织观察，对经过各种时效处理的新合金中出现的相进行了表征，以确定相变。对新合金的疲劳性能进行了研究。新合金经1063K固溶处理3.6K后，在673K时效259.2 K时，析出相均匀分布于整个样品中，析出相为α相、少量欧米伽相和β相。该合金经1063K、3.6K固溶处理后，再经673K、259.2 kS时效处理，其疲劳强度明显高于其他时效处理。在这种情况下，疲劳极限约为700兆帕。新合金的杨氏模数比Ti-6Al-4V合金的杨氏模数小得多。新合金的细胞毒性与纯钛相当。因此，提出了新型合金Ti-29Nb-13Ta-4.6Zr在生物医学领域的应用前景。(C)2003爱思唯尔科学有限公司。保留所有权利。
A beta type titanium alloy, Ti-29Nb-13Ta-4.6Zr, was newly designed and developed for biomedical applications. The new alloy contains non-toxic elements such as Nb, Ta, and Zr. In the present study, phases that appeared in the new alloy through various aging treatments were characterized by hardness tests and microstructural observations in order to identify the phase transformation. Fatigue properties of the new alloy were investigated. Young's modulus and cyto-toxicity of the new alloy were also evaluated.Precipitated phases distribute homogeneously over the whole specimen, and they are alpha phase, a small amount of omega phase, and beta phase when the new alloys are subjected to aging treatment at 673 K for 259.2 ks after solution treatment at 1063 K for 3.6 ks. The fatigue strength of the new alloy subjected to aging at 673 K for 259.2 ks after solution treatment at 1063 K for 3.6 ks is much better than when subjected to other aging treatments. In this case, the fatigue limit is around 700 MPa. Young's modulus of the new alloy is much smaller than that of Ti-6Al-4V ELI. The cyto-toxicity of the new alloy is equivalent to that of pure Ti. Therefore, it is proposed that the new alloy, Ti-29Nb-13Ta-4.6Zr, will be of considerable use in biomedical applications. (C) 2003 Elsevier Science Ltd. All rights reserved.